Augmenting maintenance of sinus rhythm in the control of atrial fibrillation by antiarrhythmic drug combinations

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 4 SUPPL., 2010, Pages

  Singh, Bramah N ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

amiodarone congeners; antiarrhythmic agents; combination of dual multiple; dronedarone

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISOPROLOL; BUDIODARONE; CARVEDILOL; CELIVARONE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; FISH OIL; FLECAINIDE; IRBESARTAN; LIDOCAINE; METOPROLOL; MEXILETINE; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; RANOLAZINE; SOTALOL; STATIN; TRANDOLAPRIL; UNINDEXED DRUG; VERAPAMIL; VERNAKALANT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ARTICLE; CARDIOVERSION; CATHETER ABLATION; DEFIBRILLATOR; HEART ATRIUM FIBRILLATION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; SINUS RHYTHM; SUDDEN DEATH; TORSADE DES POINTES; ATRIAL FIBRILLATION; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HEART ATRIUM FLUTTER; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LOW DRUG DOSE; MONOTHERAPY; QT PROLONGATION; UNSPECIFIED SIDE EFFECT;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DRUG THERAPY, COMBINATION; HUMANS; SOTALOL;

EID: 78651388918     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410377617     Document Type: Article

References (37)

1. Miyasaka Y., Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006 ; 114 (2). 119-125.
2. Fuster V., Ryden LE, Cannon DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College 1 Cardiology/American Heart Association Task Forces on Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Eur Heart J. 2006 ; 27: 1979. 1
3. Hart RG, Halperin JL Atrial fibrillation and stroke: concepts and controversies. Stroke. 2001 ; 32 (3). 803-808.
4. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H., Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998 ; 98 (10). 946-942.
5. Fetsch T., Bauer P., Edgberding R., et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004 ; 25 (16). 1385-1394.
6. Singh BN, Connolly SJ, Crijns HJ, Roy D., Kowey PR, Capucci A., et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007 ; 357 (10). 987-999.
7. Hohnloser SH, Connolly SJ, van Eickels M., et al. Effects of dronedarone on Cardiovascular event in atrial fibrillation. N Engl J Med. 2009 ; 360 (7). 668-678.
8. Arya A., Silverbauer J., Teichman SL, Milner P., Sulke N., Camm AJ A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace. 2009 ; 11 (4). 458-464.
9. Gautier P., Serre M., Cosnier-Pucheu S., et al. In vivo and vitro antiarrhythmic effects of SSR149744c in models of atrial fibrillation and ventricular arrhytmias. J Cardiovac Pharmacol. 2005 ; 45 (2). 125-135.
10. Stone PH, Gratsinsky NA, Blokh A., Huang IZ, Meng L. Anti anginal efficacy of ranolazine when added to treatment with amlidopine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006 ; 48 (3). 566-575.
11. Morrow DA, Sciric BM, Karwatowska-Prokopczuk E., et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007 ; 297 (16). 1775-1783.
12. Roy D., Row BH, Stiell IG, et al. A randomized, controlled trial of RSD1235, a novel anti-arrthythmic agent in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004 ; 44 (12). 2355-2361.
13. Orth PM, Hesketh JC, Mak CK, et al. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res. 2006 ; 70 (3). 486-496.
14. Singh BN, Vaughan Williams EM The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol. 1970 ; 39 (4). 657-667.
15. Singh BN Pharmacological Actions of Certain Cardiac Drugs and Hormones: Focus on Anti Arrhythmic Mechanisms [DPhil Thesis]. 1971. England: Herford College & University of Oxford. Published also by Futura Co, Mt Kisko, NY ; 1991: 1-98.
16. Fitzgerald J. Trails of Discovery. Class III antiarrhythmic agents: serendipity or drug design? Dialogues Cardiovasc Med. 2004 ; 9 (4). 243-252.
17. Singh BN Amiodarone: a multifaceted antiarrhythmic drug. Curr Cardiol Rep. 2006 ; 8 (5). 349-355.
18. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005 ; 352 (18). 1861-1872.
19. Singh BN Amiodarone as paradigm for developing new drugs for atrial fibrillation. J Cardiovasc Pharmacol. 2008 ; 52 (4). 300-305.
20. Altamirano J., Gallik DM, Singh BN Controlling paroxysmal atrial fibrillation by combination of amiodarone and flecainide: description of case with 15-year-follow up. J Cardiovasc Pharmacol Ther. 1996 ; 1 (4). 333-338.
21. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain Sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002 ; 106 (3). 331-336.
22. Pedersen OD, Bagger H., Kober L., Torp-Tedersen C. Trandolopril reduces the the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999 ; 100 (4). 376-380.
23. Dorian P., Singh BN Upstream therapies to prevent atrial fibrillation. Eur Heart J Suppl. 2008; 10 (suppl H). H11 - H31.
24. Sun W., Sarma JS, Singh BN Electophysiological effects of Dronedarone (SR33589) a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation. 1999 ; 100 (22). 2276-2281.
25. Patel C., Yan GX, Kowey PR Dronedarone. Circulation. 2009 ; 120 (7). 636-644.
26. Singh BN, Kowey PR Evidence and potential: beta-blockers as antiarrhythmic agents in the patient with cardiovascular disease. J Cardiovasc Pharmacol Ther. 2005 ; 10 (suppl 1). S1 - S68.
27. Singh BN β-Adrenergic blockers as anti-arrhythmic agents in the patient with cardiovascular disease. J Cardiovasc Pharmacol Ther. 2005 ; 10 (suppl 1). S3 - S14.
28. Kowey PR A review of carvedilol arrhythmia data in clinical trials. J Cardiovasc Pharmacol Ther. 2005 ; 10 (suppl 1). S59 - S68.
29. Pool-Wilson PA, Swedberg K., Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol Europrean Trial (COMET): randomized controlled trial. Lancet. 2005 ; 362 (9377). 7-13.
30. Dargie HJ Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet. 2001 ; 357 (9266). 1385-1390.
31. Ruffolo RR Jr, Gellai M., Hieble JP, Willette RN, Nichols AJ The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990 ; 38 (suppl 2). S82 - S88.
32. Dorian P. Antiarrhythmic action of β-blockers: potential mechanisms. J Cardiovasc Pharmacol Ther. 2005 ; 10 (suppl 1). S15 - S22.
33. Reiter MJ, Reiffel JA Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol. 1998 ; 82 (4A). 91-191.
34. Kawai K., Qin F., Shite J., Mao W., Fukuoka S., Liang CS Importance of antioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy. Am J Physiol Circ Physiol. 2004 ; 287 (3). H1003 - H1012.
35. Karle CA, Kreye VA, Thomas D., et al. Antiarrhythmic drug carvidelol inhibits HERG potassium channels. Cardiovasc Res. 2001 ; 49 (2). 361-370.
36. Nagele N., Eck U., Bohlmann U., Petersen B., Rödiger W. Combination therapy with carvidelol and amiodarone in patients with severe heart failure. Eur Heart Fail. 2000 ; 2 (1). 71-79.
37. Singh BN Anti arrythythmic actions of amiodarone: a profile of paradoxical agent. Am J Cardiol. 1996 ; 78 (4A). 41-45.